WO2001000185A2 - Agents therapeutiques - Google Patents

Agents therapeutiques Download PDF

Info

Publication number
WO2001000185A2
WO2001000185A2 PCT/EP2000/005541 EP0005541W WO0100185A2 WO 2001000185 A2 WO2001000185 A2 WO 2001000185A2 EP 0005541 W EP0005541 W EP 0005541W WO 0100185 A2 WO0100185 A2 WO 0100185A2
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydro
benzothiazepine
alkyl
carbon atoms
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/005541
Other languages
English (en)
Other versions
WO2001000185A3 (fr
Inventor
Ian Charles Kilpatrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Priority to JP2001505895A priority Critical patent/JP2003513008A/ja
Priority to MXPA01013420A priority patent/MXPA01013420A/es
Priority to EP00945759A priority patent/EP1218010A2/fr
Priority to AU59736/00A priority patent/AU5973600A/en
Priority to CA002376023A priority patent/CA2376023A1/fr
Publication of WO2001000185A2 publication Critical patent/WO2001000185A2/fr
Anticipated expiration legal-status Critical
Publication of WO2001000185A3 publication Critical patent/WO2001000185A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the use of 2,3,4,5-tetrahydro-1 ,4- benzothiazepines in the treatment of obesity, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, and as an aid to smoking cessation.
  • n 0, 1 or 2;
  • , and R2 independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo);
  • R ⁇ to R1 1 independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof; with the proviso that:
  • the present invention provides a method of treating obesity and related conditions comprising the administration to a mammal, particularly a human, in need thereof of a therapeutically effective amount of a compound of formula I
  • n 0, 1 or 2;
  • , and R2 independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo);
  • R8 to Ri 1 independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof.
  • related conditions means eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, and as an aid to smoking cessation.
  • n 0 or 1 ;
  • Ri , R2, R ⁇ and R7 are each H;
  • R3 and R4 are independently H or methyl; or together represent imino, methylimino, phenylimino, hydroxyimino or methoxyimi ⁇ o;
  • R5 is H or methyl, or when R3 and R4 are independently H or methyl, R5 is H, methyl, formyl, acetyl, propionyl, benzoyl, methylsulphinyl, methylsulphonyl or ethylsulphonyl;
  • R8 is H, methyl, fluoro or chloro
  • R9, R10 and R11 are each H; or a pharmaceutically acceptable salt thereof.
  • Preferred compounds of formula I are selected from:
  • More preferred compounds of formula I are selected from:
  • Most preferred compounds of formula I are selected from: 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1 ,4-benzothiazepine;
  • a particularly preferred compound of formula I is: 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1 ,4-benzothiazepine; its stereoisomers; and pharmaceutically acceptable salts thereof.
  • n 0, 1 or 2;
  • , and R2 independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo);
  • R8 to R-11 independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof; with the proviso that:
  • Ri and R2 are independently H or methyl
  • R3 and R4 are independently H or methyl; or together represent imino, methylimino, phenylimino, hydroxyimino or methoxyimino;
  • R5 is H or methyl, and when R3 and R4 are H or methyl, R5 is H, methyl, formyl, acetyl, propionyl, benzoyl, methylsulphinyl, methylsulphonyl or ethylsulphonyl;
  • R6 and R7 are each H; and one of R8 to Rn is H, fluoro, chloro, bromo, iodo, methyl (optionally substituted with one or more halo), methoxy (optionally substituted by one or more halo),nitro, cyano, carboxy, acetyl, dimethylcarbamoyl or dimethylsulphamoyl; the remainder of Rs to
  • R-11 being H; their stereoisomers; and pharmaceutically acceptable salts thereof.
  • R3 and R4 are H, or together are methylimino, phenylimino, hydroxyimino or methoxyimino;
  • R5 is H or methyl, and when R3 and R4 are H, R5 is H, methyl, formyl, acetyl, propionyl, benzoyl, methylsulphinyl, methylsulphonyl, or ethylsulphonyl;
  • R8 is H, methyl, fluoro or chloro;
  • Rg to Ri 1 are all H; their stereoisomers; and pharmaceutically acceptable salts thereof.
  • the compounds of the present invention may prepared and formulated into pharmaceutical formulations as described in WO94/11360.
  • the compound of formula I may be administered in any of the known pharmaceutical dosage forms.
  • the amount of the compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound to be administered will be in the range 0.1 to 1000 mg preferably 1 to 500 mg per day given in one or more doses.
  • Oral dosage forms are the preferred compositions for use in the present invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oil suspensions.
  • the excipients used in the preparation of these compositions are theexcipients known in the pharmacist's art.
  • Tablets may be prepared from a mixture of the active compound with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders, for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods.
  • the tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate.
  • the tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention.
  • Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate.
  • capsules for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner.
  • the contents of the capsule may be formulated using known methods so as to give sustained release of the active compound.
  • the tablets and capsules may conveniently each contain 1 to 500 mg of the active compound.
  • the tablets and capsules each contain 5, 10, 15, 20, 25, 30, 50, 100 ,250 or ⁇ OOmg.
  • dosage forms for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy-methylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil.
  • the active compound may be formulated into granules with or without additional excipients.
  • the granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion.
  • the granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.
  • the therapeutically active compounds of formula I may be formulated into a composition which the patient retains in his mouth so that the active compound is administered through the mucosa of the mouth.
  • Dosage forms suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.
  • Dosage forms suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.
  • Dosage forms for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally.
  • a suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol.
  • the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base.
  • the amount of active compound contained in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.
  • the therapeutically active compound of formula I may be formulated into a composition which is dispersed as an aerosol into the patients oral or nasal cavity.
  • Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile propellant.
  • the therapeutically active compounds of formula I used in the method of the present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body.
  • Internal sources include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused.
  • the support may be a single body containing all of the compound or a series of several bodies each containing part of the compound to be delivered.
  • the amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.
  • compositions containing a therapeutically effective amount of a compound of Formula I may be used to treat obesity and related conditions including eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperiipidaemia, and stress in mammals particularly humans, and as an aid to smoking cessation in human beings.
  • eating disorders such as bulimia, anorexia, snacking and binge eating
  • non-insulin dependent diabetes mellitus such as hyperglycaemia, hyperiipidaemia, and stress in mammals particularly humans
  • the amount of active compound administered per day is in the range 1 to 1000 mg preferably 5 to 500 mg given in single or divided doses at one or more times during the day.
  • the present invention provides the use of a compound of Formula I in the manufacture of a medicament for use in the treatment of obesity and related conditions including eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperiipidaemia, and stress, and as an aid to smoking cessation.
  • eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperiipidaemia, and stress, and as an aid to smoking cessation.
  • the present invention also provides a method of treating obesity and related conditions including eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperiipidaemia and stress which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.
  • eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperiipidaemia and stress which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.
  • the present invention also provides a method of reducing the craving to smoke in human beings which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.
  • the present invention also provides a method of reducing weight gain after smoking cessation in human beings which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.
  • the compounds of the present invention may be useful in the treatment or prevention of metabolic diseases and conditions arising therefrom, for example non exercise activity thermogenesis and increased metabolic rate.
  • the compounds of the present invention may be useful in preventing cardiovascular disease, and in reducing platelet adhesiveness, in aiding weight loss after pregnancy and in aiding weight loss after smoking cessation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Cette invention se rapporte à un procédé servant à traiter l'obésité et les états apparentés et consistant à cet effet à administrer à un mammifère, notamment l'homme, nécessitant un tel traitement une quantité thérapeutiquement efficace d'un composé représenté par la formule (I), où: n = 0, 1 ou 2; R1 et R2 représentent séparément H ou alkyle ayant 1 à 4 atomes de carbone (éventuellement substitué par un ou plusieurs halo); R3 et R4 représentent séparément H ou alkyle ayant 1 à 4 atomes de carbone; ou représentent ensemble un groupe de formule =NR12, où R12 représente H, hydroxy, alkyle ayant 1 à 4 atomes de carbone, phényle ou alcoxy ayant 1 à 4 atomes de carbone; chaque alkyle, phényle et alcoxy étant éventuellement substitué par un ou plusieurs halo; R5 représente: (a) H, (b) alkyle ayant 1 à 4 atomes de carbone, (c) un groupe de formule -COR13, où R13 représente H, alkyle ayant 1 à 4 atomes de carbone ou phényle, lorsque R3 et R4 représentent H ou alkyle (éventuellement substitué par un ou plusieurs halo), ou (d) un groupe de formule -S(O)pR14, où p = 1 ou 2 et R14 représente alkyle ayant 1 à 4 atomes de carbone ou phényle, lorsque R3 et R4 représentent H ou alkyle (éventuellement substitué par un ou plusieurs halo); chaque alkyle et phényle étant éventuellement substitué par un ou plusieurs halo; R6 et R7 représentent chacun H; les éléments R8 à R11 représentent séparément H, halo, cyano, nitro, alkyle ayant 1 à 4 atomes de carbone, alcoxy ayant 1 à 4 atomes de carbone, alcanoyle ayant 1 à 4 atomes de carbone, carboxy, alcanoyloxy ayant 1 à 4 atomes de carbone, carbamoyle (éventuellement substitué par alkyle ayant 1 à 4 atomes de carbone), ou sulfamoyle (éventuellement substitué par alkyle ayant 1 à 4 atomes de carbone); chaque alkyle, alcoxy, alcanoyle ou alcanoyloxy étant éventuellement substitué par un ou plusieurs halo; leurs stéréo-isomères; et des sels de ceux-ci acceptables sur le plan pharmaceutique.
PCT/EP2000/005541 1999-06-24 2000-06-16 Agents therapeutiques Ceased WO2001000185A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001505895A JP2003513008A (ja) 1999-06-24 2000-06-16 治療薬
MXPA01013420A MXPA01013420A (es) 1999-06-24 2000-06-16 Agentes terapeuticos.
EP00945759A EP1218010A2 (fr) 1999-06-24 2000-06-16 1,4-benzothiazepines dans le traitement des desordres lies a l'obesite
AU59736/00A AU5973600A (en) 1999-06-24 2000-06-16 Therapeutic agents
CA002376023A CA2376023A1 (fr) 1999-06-24 2000-06-16 Agents therapeutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9914745.6 1999-06-24
GBGB9914745.6A GB9914745D0 (en) 1999-06-24 1999-06-24 Therapeutic agents

Publications (2)

Publication Number Publication Date
WO2001000185A2 true WO2001000185A2 (fr) 2001-01-04
WO2001000185A3 WO2001000185A3 (fr) 2002-04-11

Family

ID=10855956

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005541 Ceased WO2001000185A2 (fr) 1999-06-24 2000-06-16 Agents therapeutiques

Country Status (7)

Country Link
EP (1) EP1218010A2 (fr)
JP (1) JP2003513008A (fr)
AU (1) AU5973600A (fr)
CA (1) CA2376023A1 (fr)
GB (1) GB9914745D0 (fr)
MX (1) MXPA01013420A (fr)
WO (1) WO2001000185A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8247403B2 (en) 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
WO2013064231A1 (fr) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag Sulfonamides à sept chaînons comme modulateurs des récepteurs gamma orphelins associés à un récepteur de l'acide rétinoïque (rorγ, nr1f3)
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US8815875B2 (en) 2008-11-12 2014-08-26 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
US8853198B2 (en) 2012-04-18 2014-10-07 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1603450A4 (fr) 2003-03-07 2009-07-29 Univ Columbia Procedes utilisant le recepteur de la ryanodine de type 1
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
BR112023009303A2 (pt) * 2020-11-17 2024-02-06 Armgo Pharma Inc Agentes para tratar distúrbios envolvendo receptores de rianodina

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361760A (en) * 1963-03-21 1968-01-02 Squibb & Sons Inc Benzothiazepines
US3794639A (en) * 1966-03-10 1974-02-26 Squibb & Sons Inc Benzoxazepines and benzothiazepines
JP2871811B2 (ja) * 1990-02-28 1999-03-17 サントリー株式会社 縮合７員環系化合物
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
JP3093419B2 (ja) * 1992-03-30 2000-10-03 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
KR100313649B1 (ko) * 1992-11-09 2002-02-28 더 부츠 캄파니 피엘씨 신경계질환치료제로서유용한1,4-벤조티아제핀,이의제조방법및이를포함하는약제학적조성물
JPH08505374A (ja) * 1992-12-11 1996-06-11 チバ−ガイギー アクチェンゲゼルシャフト ベンズアゼピノン誘導体
IL108633A (en) * 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
IL108634A0 (en) * 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
DE69815180T2 (de) * 1997-03-14 2004-04-29 Aventis Pharma Deutschland Gmbh Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
ATE344667T1 (de) * 1997-08-22 2006-11-15 Kaken Pharma Co Ltd Amide zur förderung der ausschüttung von wachstumshormonen

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US8247403B2 (en) 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
US8815875B2 (en) 2008-11-12 2014-08-26 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
WO2013064231A1 (fr) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag Sulfonamides à sept chaînons comme modulateurs des récepteurs gamma orphelins associés à un récepteur de l'acide rétinoïque (rorγ, nr1f3)
US8853198B2 (en) 2012-04-18 2014-10-07 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors

Also Published As

Publication number Publication date
WO2001000185A3 (fr) 2002-04-11
CA2376023A1 (fr) 2001-01-04
MXPA01013420A (es) 2002-07-22
EP1218010A2 (fr) 2002-07-03
AU5973600A (en) 2001-01-31
GB9914745D0 (en) 1999-08-25
JP2003513008A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
US5942549A (en) Improving glucose tolerance
EP0236684B1 (fr) Galanthamine ou ses analogues pour le traitement de la maladie d'Alzheimer
EP0514452B2 (fr) Utilisation d'agents de sensibilisation a l'insuline afin de traiter l'hypertension
AU2016205138A1 (en) ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
JP2007533733A (ja) 食物摂取管理の方法
EP2129400A2 (fr) Compositions pharmaceutiques comprenant de la flibanserine et un agent additionelle pour le traitement de desordres sexuels
ES2199374T3 (es) Derivados de 1-(1-(4-clorofenil)ciclobutil)-3-metilbutilamina para reducir el nivel de acido urico en seres humanos.
EP1039900B1 (fr) Agents therapeutiques contenant sibutramine et orlistat
JPH0637395B2 (ja) ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤
EP1218010A2 (fr) 1,4-benzothiazepines dans le traitement des desordres lies a l'obesite
RU2004131214A (ru) Способы лечения когнитивных расстройств
WO1998027982A1 (fr) Composition contenant de l'acide ascorbique
WO2000056313A1 (fr) Procede de lutte contre le gain de poids associe a des medicaments therapeutiques
HUT50440A (en) Process for producing pharmaceutical compositions for treating schizophrenia
JP2549480B2 (ja) 排尿障害改善剤
JP2001526217A (ja) 血管性頭痛に対する局所麻酔薬の新規な使用
WO1995028933A1 (fr) Utilisation de derives arylpiperazines dans le traitement de la maladie de parkinson et de psychoses
CA2376886A1 (fr) Agents therapeutiques
WO1997023477A1 (fr) Derives de dibenzothiepine et compositions pharmaceutiques
AU2730800A (en) Method to aid smoking cessation
US20060063813A1 (en) Organic compounds
JP2002514208A (ja) 痴呆の治療及び予防におけるシクロオキシゲナーゼ−２阻害剤の使用方法
NL8000332A (nl) Werkwijze voor het bereiden van een geneesmiddel dat een benzoc 1,6 naftyridine bevat.
US20040242667A1 (en) Method of using cyclooxegenase-2 inhibitors in the treatment and prevention of dementia
MXPA01007833A (es) Metodo para prevenir o reducir eventos cardiovasculares asociados con intervencion de la arteria coronaria.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2376023

Country of ref document: CA

Ref country code: CA

Ref document number: 2376023

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/013420

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 505895

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000945759

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10019110

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000945759

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000945759

Country of ref document: EP